SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
8,73Â USD
arrow_upward
+0,58%(+0,050) 1d
8,73Â USD
0,00% (0,00)
bedtimeFora d'horari
Tancat: 7 d’oct., 16:00:00 GMT-4 · USD
search
Tots els sÃmbols
| SÃmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadÃstiques principals per a SGIOY...
Obre
8,74Â USD
Alt
9,06Â USD
Baix
8,47Â USD
Capitalització borsà ria
2,37Â B
Volum mitjÃ
160,83Â k
Volum
0,00
Alt 52 setmanes
12,00Â USD
Baix 52 setmanes
7,65Â USD
Versió beta
0,07
Accions en circulació
1779,26Â M
Nombre d'empleats
6Â k
Obre
8,74Â USD
Alt
9,06Â USD
Baix
8,47Â USD
Capitalització borsà ria
2,37Â B
Volum mitjÃ
160,83Â k
Volum
0,00
Alt 52 setmanes
12,00Â USD
Baix 52 setmanes
7,65Â USD
Versió beta
0,07
Accions en circulació
1779,26Â M
Nombre d'empleats
6Â k
NotÃcies
De fonts web i partners de notÃcies
AD HOC NEWS
·
fa 6 hores
Shionogi stock shifts focus to its Actair transfer
AD HOC NEWS
·
fa 1 dia
Shionogi agrees to buy IntraBio for USD 2.00 billion: what it means for Shionogi stock
Fierce Pharma
·
fa 2 dies
Shionogi strikes $2B deal for IntraBio hot off FDA label expansion
Perfil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Sobre Shionogi 2 ADR Representing 1 Ord Shs
Conseller delegatIsao Teshirogi
Empleats6,22Â k
Fundació1878
Seu principal-
Sector-
Lloc webshionogi.com